Hepatitis B and C viruses remain leading causes of disability and premature death worldwide. In May 2016, the UK adopted the Global Health Sector Strategy to eliminate viral hepatitis as a public health threat by 2030. Significant advances have been made, notably the availability of short courses of all-oral direct-acting antivirals (DAAs) for hepatitis C, which cure more than 90% of individuals. Despite improved access to treatment, an estimated 93,000 people in the UK were still living with HCV at the end of 2021, with three-quarters unaware of their infection. This review summarizes key advances in hepatitis C treatment and prevention and provides a practical approach to managing individuals with HCV.

In response to the viral hepatitis pandemic, the first global health sector strategy on viral hepatitis was launched in 2016, aiming to eliminate it as a public health threat by 2030. Recent advances in care, especially the availability of DAAs, have significantly improved treatment outcomes. However, challenges remain, particularly in identifying and treating the estimated 92,900 people still living with HCV in the UK, many of whom are unaware of their infection. Enhanced prevention and treatment strategies, including improved access to testing and care for at-risk populations, are crucial to achieving the goal of HCV elimination.

Reference: O’ Kane R, Hathorn E. Hepatitis C: recent advances and practical management. Frontline Gastroenterol. 2023 Jun 13;14(5):415-421. doi: 10.1136/flgastro-2022-102373. PMID: 37581179; PMCID: PMC10423602.